The role of Alfacyte™
Transformational
potential in the global
fight against viral respiratory diseases
Our lead candidate, Alfacyte™, is being developed to combat respiratory viral infections, which pose a major and growing global healthcare threat.
Global experience
Dynamic team and
clear business model
ILCT’s executive team and board are globally experienced and have a proven track record of success. Based in BioCity, outside Glasgow, Scotland, and with outreach in London, the company boasts strong academic links with Universities, St Andrews, Edinburgh, Strathclyde and Liverpool School of Tropical Medicine.
Our business Model is to take assets through Phase I/IIa clinical trials then outlicense / sell.